JP2016512531A5 - - Google Patents

Download PDF

Info

Publication number
JP2016512531A5
JP2016512531A5 JP2016501395A JP2016501395A JP2016512531A5 JP 2016512531 A5 JP2016512531 A5 JP 2016512531A5 JP 2016501395 A JP2016501395 A JP 2016501395A JP 2016501395 A JP2016501395 A JP 2016501395A JP 2016512531 A5 JP2016512531 A5 JP 2016512531A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
cataplexy
treatment
formula
enantiomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016501395A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016512531A (ja
JP6530741B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/023969 external-priority patent/WO2014164969A1/en
Publication of JP2016512531A publication Critical patent/JP2016512531A/ja
Publication of JP2016512531A5 publication Critical patent/JP2016512531A5/ja
Application granted granted Critical
Publication of JP6530741B2 publication Critical patent/JP6530741B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016501395A 2013-03-13 2014-03-12 カタプレキシーの治療 Active JP6530741B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361778998P 2013-03-13 2013-03-13
US61/778,998 2013-03-13
PCT/US2014/023969 WO2014164969A1 (en) 2013-03-13 2014-03-12 Treatment of cataplexy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019093823A Division JP2019147830A (ja) 2013-03-13 2019-05-17 カタプレキシーの治療

Publications (3)

Publication Number Publication Date
JP2016512531A JP2016512531A (ja) 2016-04-28
JP2016512531A5 true JP2016512531A5 (https=) 2019-01-31
JP6530741B2 JP6530741B2 (ja) 2019-06-12

Family

ID=51530017

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016501395A Active JP6530741B2 (ja) 2013-03-13 2014-03-12 カタプレキシーの治療
JP2019093823A Pending JP2019147830A (ja) 2013-03-13 2019-05-17 カタプレキシーの治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019093823A Pending JP2019147830A (ja) 2013-03-13 2019-05-17 カタプレキシーの治療

Country Status (21)

Country Link
US (7) US9359290B2 (https=)
EP (1) EP2968208B1 (https=)
JP (2) JP6530741B2 (https=)
KR (1) KR102192554B1 (https=)
CN (1) CN105431142B (https=)
AU (1) AU2014248849B2 (https=)
BR (1) BR112015022197B1 (https=)
CA (1) CA2905457A1 (https=)
DK (1) DK2968208T3 (https=)
ES (1) ES2927675T3 (https=)
HR (1) HRP20221018T1 (https=)
HU (1) HUE060060T2 (https=)
MX (1) MX381381B (https=)
MY (1) MY177740A (https=)
PH (1) PH12015502075B1 (https=)
PT (1) PT2968208T (https=)
RU (2) RU2689984C2 (https=)
SG (1) SG11201507121RA (https=)
SI (1) SI2968208T1 (https=)
TW (2) TWI684450B (https=)
WO (1) WO2014164969A1 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2435403T3 (es) * 2005-06-08 2013-12-19 Sk Biopharmaceuticals Co., Ltd. Tratamiento de trastornos del sueño y vigilia
KR102173587B1 (ko) 2009-06-22 2020-11-04 에스케이바이오팜 주식회사 피로의 치료 또는 예방 방법
US9359290B2 (en) * 2013-03-13 2016-06-07 Jazz Pharmaceuticals International Iii Limited Treatment of cataplexy
KR102309836B1 (ko) 2013-07-18 2021-10-12 에스케이바이오팜 주식회사 비만의 치료
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US10195151B2 (en) * 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
ES2970887T3 (es) 2016-09-06 2024-05-31 Axsome Malta Ltd Forma de solvato de carbamato de (R)-2-amino-3-fenilpropilo
EP4316592A3 (en) 2016-10-06 2024-05-01 Axsome Malta Ltd. Carbamoyl phenylalaninol compounds and uses thereof
AU2018278332B2 (en) * 2017-06-02 2022-05-19 Jazz Pharmaceuticals Ireland Limited Methods and compositions for treating excessive sleepiness
KR102643275B1 (ko) 2017-07-31 2024-03-04 재즈 파마슈티칼즈 아일랜드 리미티드 카바모일 페닐알라니놀 유사체 및 이의 용도
JP2020533415A (ja) * 2017-09-12 2020-11-19 オービッド・セラピューティクス・インコーポレイテッドOvid Therapeutics Inc. ナルコレプシーの処置におけるガボキサドールの使用
US12419832B2 (en) 2018-01-29 2025-09-23 Cognos Therapeutics, Inc. Intratumoral delivery of bortezomib
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
WO2021113163A1 (en) * 2019-12-03 2021-06-10 Axsome Therapeutics, Inc. Use of reboxetine to treat nervous system disorders
CN112888430A (zh) * 2018-10-15 2021-06-01 艾克萨姆治疗公司 瑞波西汀治疗发作性睡病的用途
EP3930702A1 (en) 2019-03-01 2022-01-05 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
JP2023504685A (ja) * 2019-12-03 2023-02-06 アクスサム セラピューティクス インコーポレイテッド 神経系障害を治療するためのレボキセチンを含む組成物
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
KR102390194B1 (ko) * 2020-08-03 2022-04-25 셀라이온바이오메드 주식회사 페닐알킬 카바메이트 화합물을 포함하는 Kca3.1채널 매개질환 치료용 조성물
WO2022076824A1 (en) 2020-10-08 2022-04-14 Jazz Pharmaceuticals Ireland Limited Sodium oxybate to treat idiopathic hypersomnia
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
KR20260033050A (ko) 2023-06-29 2026-03-10 액섬 테라퓨틱스, 인크. 수유 여성에게 솔리암페톨을 투여하는 방법
WO2025042959A1 (en) * 2023-08-21 2025-02-27 Axsome Therapeutics, Inc. Use of solriamfetol for the treatment of orphan diseases
US12565478B1 (en) 2025-01-21 2026-03-03 Axsome Therapeutics, Inc. (S)-2-((S)-(2-ethoxyphenoxy)(phenyl)methyl)-4-nitrosomorpholine

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US178429A (en) * 1876-06-06 Improvement in hulling-machines
NZ260667A (en) 1993-06-10 1997-05-26 Lilly Co Eli Preventing emesis or treating sexual dysfunction using tetrahydrobenz[cd]indole 6-carboxamides
KR100197892B1 (ko) 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
US5756817C1 (en) 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173862B1 (ko) 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
KR0173863B1 (ko) 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
EP0873308B1 (en) 1996-10-10 2002-01-02 SK Corporation O-carbamoyl-phenylalaninol compounds and their pharmaceutically useful salts
WO1998017636A1 (en) 1996-10-22 1998-04-30 Ortho Pharmaceutical Corporation Phenylalaninol derivatives for the treatment of central nervous system disorders
US6204245B1 (en) * 1999-09-17 2001-03-20 The Regents Of The University Of California Treatment of narcolepsy with immunosuppressants
GB0109103D0 (en) * 2001-04-11 2001-05-30 Pfizer Ltd Novel compounds
US20030207857A1 (en) 2001-04-11 2003-11-06 Adam Mavis D. Phenyl heterocyclyl ethers
US20050080268A1 (en) 2003-10-08 2005-04-14 Yong-Moon Choi Process of preparing O-carbamoyl compounds in the presence of active amine group
ATE490959T1 (de) 2004-03-31 2010-12-15 Janssen Pharmaceutica Nv Heterocyclische nichtimidazolverbindungen als modulatoren des histamin-h3-rezeptors
KR20070100686A (ko) * 2004-09-07 2007-10-11 오르펀 메디칼, 인크. 개선된 ghb 조성물
CA2587481A1 (en) 2004-10-28 2006-05-11 Sk Corporation Phenylalkylamino carbamates adjunctive therapy for depression
ES2435403T3 (es) * 2005-06-08 2013-12-19 Sk Biopharmaceuticals Co., Ltd. Tratamiento de trastornos del sueño y vigilia
ES2344469T3 (es) 2005-06-22 2010-08-27 Sk Holdings Co., Ltd. Tratamiento de disfuncion sexual.
AU2005335241B9 (en) 2005-07-26 2012-12-20 Sk Biopharmaceuticals Co., Ltd. Methods for treating substance-related disorders
FR2903904A1 (fr) * 2006-07-21 2008-01-25 Bioprojet Soc Civ Ile Association de modafinil et d'un antagoniste ou agoniste inverse du recepteur h3
CA2673487A1 (en) 2006-10-13 2008-04-24 Janssen Pharmaceutica Nv Phenylalkylamino carbamate compositions
JP2010510175A (ja) * 2006-11-10 2010-04-02 ディメリックス・バイオサイエンス・ピーティーワイ・リミテッド 甲状腺刺激ホルモン放出ホルモン受容体−オレキシン受容体のヘテロダイマー/オリゴマー
KR102173587B1 (ko) 2009-06-22 2020-11-04 에스케이바이오팜 주식회사 피로의 치료 또는 예방 방법
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
MX350745B (es) 2009-11-06 2017-09-14 Sk Biopharmaceuticals Co Ltd * El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia.
US8895609B2 (en) 2009-11-06 2014-11-25 Sk Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9359290B2 (en) * 2013-03-13 2016-06-07 Jazz Pharmaceuticals International Iii Limited Treatment of cataplexy

Similar Documents

Publication Publication Date Title
JP2016512531A5 (https=)
JP2015532295A5 (https=)
RU2015143610A (ru) Лечение катаплексии
JP2019524883A5 (https=)
JP2014500295A5 (https=)
JP2016517851A5 (https=)
JP2016534063A5 (https=)
JP2018535967A5 (https=)
JP2016518437A5 (https=)
JP2012530779A5 (https=)
JP2012521994A5 (https=)
JP2015505296A5 (https=)
JP2010077141A5 (https=)
JP2017528503A5 (https=)
JP2015508103A5 (https=)
JP2018524304A5 (https=)
JP2019526596A5 (https=)
JP2017505293A5 (https=)
JP2020502047A5 (https=)
JP2017531619A5 (https=)
JP2018538273A5 (https=)
JP2017522352A5 (https=)
JP2014505107A5 (https=)
JP2019520344A5 (https=)
JP2014505017A5 (https=)